Medical Therapies buys midkine IP
Thursday, 03 July, 2008
Sydney pharma Medical Therapies [ASX: MTY] has completed the purchase of the IP surrounding midkine protein-related technology assets from Japanese company Cell Signals Inc after receiving shareholder approval.
Cell Signals today traded all midkine protein-related IP rights to Medical Therapies, in exchange for 20 million shares of Medical Therapies stock.
These include patents, trademarks, manufacturing information and technical know-how, on top of all Cell Signals' stocks of midkine protein and reagents.
The agreement was announced in April. Midkine is a neurite growth promoting factor, active in oncogenesis and inflammation.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
